Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMahasweta GooptuSBStephanie Bo‐SubaitSSSarah Smith

Discussion

Loading...

Member takes

Overview

Phase II study shows improved overall survival and reduced non-relapse mortality with PTCy in adult HCT recipients, suggesting strategies to mitigate infection risk.

Key Points

  • One-year overall survival estimate was 79.6%, indicating positive outcomes for patients with HLA-mismatched donors.
  • Cytokine release syndrome occurred in 28.0% of participants within 100 days post HCT, necessitating careful monitoring.
  • Participants received peripheral blood stem cell allografts with PTCy-based prophylaxis, showcasing potential in GVHD management.
  • Results highlight the importance of infection risk mitigation strategies to enhance outcomes and support further exploration of PTCy protocols.

Cite This Study

Gooptu et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df00https://doi.org/10.1182/blood-2025-4232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-transplant cyclophosphamide based GVHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants2025
  2. 2Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  3. 3Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  4. 4Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis2025
  5. 5Safety and efficacy of post transplant cyclophosphamide vs tacrolimus plus methotrexate for gvhd prophylaxis in myelofibrosis2025